Biotechnology is increasingly viewed in Washington through a national security lens. What was once treated primarily as a matter of public health and commercial competition is now the subject of an expanding web of investment restrictions, export controls, data-transfer prohibitions, and procurement bans. For companies operating in the pharmaceutical, biotechnology, and broader life science sectors, the regulatory landscape is shifting quickly, and several measures under discussion in Washington could materially expand the universe of restricted activities and counterparties. This Legal Update summarizes the principal biotechnology-related national security concerns motivating policymakers, surveys the legal authorities currently in force, and previews potential measures which could affect the industry in the near future.

Full analysis : China’s rise in biotechnology is viewed seriously by Washington through national security lens.